查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1642929

肾臟生物标记市场 - 全球产业规模、份额、趋势、机会和预测，按产品类型、技术、最终用户、地区和竞争细分，2020-2030F

Renal Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Technique, By End user, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024年全球肾臟生物标记市场估值为13.1亿美元，预计2030年将达到19.7亿美元，预测期内复合年增长率为7.25%。出现了显着增长。肾臟生物标记在诊断和监测各种肾臟相关疾病中发挥着至关重要的作用，使其成为医疗保健领域的宝贵工具。肾臟生物标记是在血液、尿液或其他体液中发现的分子或物质，提供有关肾臟状态和功能的有价值的资讯。这些生物标记可以帮助医疗保健专业人员在早期阶段检测肾臟疾病，评估肾损伤的严重程度并监测治疗的有效性。常见的肾臟生物标记包括血清肌酸酐、尿液白蛋白和估计肾小球滤过率 (eGFR)。慢性肾臟病（CKD）和其他肾臟相关疾病（例如急性肾损伤（AKI）和糖尿病肾病变）的盛行率不断增加，是肾臟生物标记市场的主要驱动力。人口老化和全球糖尿病流行加剧了肾臟疾病负担。早期诊断和介入对于有效管理肾臟疾病至关重要。肾臟生物标记提供了一种非侵入性且方便的诊断和监测肾臟疾病的方法，使其成为医疗保健提供者不可或缺的工具。技术的进步导致了更灵敏和特异的肾臟生物标记检测的发展。新型生物标记和改进的检测方法正在提高肾臟疾病诊断和预后的准确性。个人化医疗的趋势也正在影响肾臟生物标记市场。基于患者独特的生物标记特征的客製化治疗计划变得越来越普遍，从而改善了肾臟疾病的整体管理。

市场概况
预测期 2026-2030
2024 年市场规模 13.1亿美元
2030 年市场规模 19.7亿美元
2025-2030 年复合年增长率 7.25%
成长最快的细分市场 血清胱抑素C
最大的市场 北美洲

主要市场驱动因素

肾臟疾病盛行率上升

增加药物开发和临床试验

主要市场挑战

有限的生物标记验证

监管障碍

报销挑战

竞争与市场饱和

资料隐私和道德问题

临床实用性和医生采用

主要市场趋势

技术进步

细分市场洞察

产品类型见解

最终使用者见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：全球肾臟生物标记市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型（功能性生物标记、血清肌酸酐、血清胱抑素C、尿液白蛋白、上调蛋白、嗜中性球明胶酶相关脂质运载蛋白(NGAL)、肾损伤分子-1、INTERLEUKIN-18 、其他）
    • 依技术分类（酵素连结免疫吸附测定法 (ELISA)、颗粒增强比浊免疫测定 (PETIA)、比色测定、化学发光酶免疫测定法 (CLIA)、液相层析质谱 (LC-MS)）
    • 按最终使用者（医院和诊所、诊断实验室、其他）
    • 按地区
    • 按公司划分 (2024)
  • 市场地图
    • 依产品类型
    • 依技术
    • 按最终用户
    • 按地区

第 5 章：亚太地区肾臟生物标记市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 依技术
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第 6 章：欧洲肾臟生物标记市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 依技术
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 7 章：北美肾臟生物标记市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 依技术
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 8 章：南美洲肾臟生物标记市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 依技术
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 9 章：中东和非洲肾臟生物标记市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依产品类型
    • 依技术
    • 按最终用户
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 埃及

第 10 章：市场动态

  • 司机
  • 挑战

第 11 章：市场趋势与发展

  • 最新动态
  • 产品发布
  • 併购

第 12 章：全球肾臟生物标记市场：SWOT 分析

第 13 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • Abbott Laboratories
  • Beckman Coulter Inc. (Danaher Corporation)
  • bioMerieux SA
  • BioPorto A/S
  • Bio-Rad Laboratories Inc.
  • Enzo Biochem Inc.
  • F. Hoffmann-La Roche AG
  • PerkinElmer Inc.
  • Randox Laboratories Ltd.
  • Siemens AG
  • Thermo Fisher Scientific Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 20081

Global Renal Biomarkers Market was valued at USD 1.31 Billion in 2024 and is expected to reach USD 1.97 Billion by 2030 with a CAGR of 7.25% during the forecast period.The global renal biomarkers market has witnessed significant growth in recent years, driven by an increasing prevalence of kidney diseases and a growing demand for early disease detection and management. Renal biomarkers play a crucial role in diagnosing and monitoring various kidney-related disorders, making them invaluable tools in the field of healthcare. Renal biomarkers are molecules or substances that are found in the blood, urine, or other bodily fluids and provide valuable information about the status and function of the kidneys. These biomarkers can help healthcare professionals detect kidney diseases at an early stage, assess the severity of kidney injury, and monitor the effectiveness of treatment. Common renal biomarkers include serum creatinine, urinary albumin, and estimated glomerular filtration rate (eGFR). The increasing prevalence of chronic kidney disease (CKD) and other kidney-related disorders, such as acute kidney injury (AKI) and diabetic nephropathy, is a primary driver of the renal biomarkers market. Aging populations and the global diabetes epidemic have contributed to the growing burden of kidney diseases. Early diagnosis and intervention are essential for managing kidney diseases effectively. Renal biomarkers provide a non-invasive and convenient means of diagnosing and monitoring kidney disorders, making them indispensable tools for healthcare providers. Advances in technology have led to the development of more sensitive and specific renal biomarker assays. Novel biomarkers and improved detection methods are enhancing the accuracy of kidney disease diagnosis and prognosis. The trend towards personalized medicine is also impacting the renal biomarkers market. Tailored treatment plans based on a patient's unique biomarker profile are becoming more common, improving the overall management of kidney diseases.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.31 Billion
Market Size 2030USD 1.97 Billion
CAGR 2025-20307.25%
Fastest Growing SegmentSerum Cystatin C
Largest MarketNorth America

Key Market Drivers

Rising Prevalence of Kidney Diseases

Kidney diseases are becoming increasingly prevalent worldwide, posing a significant healthcare challenge. These conditions can lead to severe health complications and, in some cases, even be life-threatening. The rising incidence of kidney diseases has prompted extensive research in the medical field, leading to the development and adoption of renal biomarkers. These biomarkers have played a crucial role in early diagnosis, monitoring, and treatment of kidney diseases, driving the global renal biomarkers market forward. Kidney diseases encompass a range of conditions affecting the vital organs responsible for filtering waste products and excess fluid from the blood, maintaining electrolyte balance, and producing hormones to regulate blood pressure and red blood cell production. Common kidney diseases include chronic kidney disease (CKD), acute kidney injury (AKI), kidney stones, and polycystic kidney disease (PKD).

The Centers for Disease Control and Prevention's (CDC) 2023 report on Chronic Kidney Disease (CKD) in the United States indicates that CKD is slightly more prevalent in women (14%) compared to men (12%). Around 20% of non-Hispanic Black adults are affected by CKD, while approximately 12% of non-Hispanic White adults and 14% of non-Hispanic Asian adults have the condition. The global prevalence of kidney diseases has been on the rise for several reasons. First and foremost is the increasing prevalence of risk factors such as diabetes, hypertension, and obesity. These conditions are known to be significant contributors to kidney disease development. Additionally, an aging population and lifestyle factors like smoking and poor dietary choices have added to the burden of kidney diseases. Inadequate awareness and late-stage diagnosis have exacerbated the problem. Kidney diseases often progress silently, with symptoms only becoming apparent in the advanced stages. Early detection is crucial for effective intervention and management, making renal biomarkers a vital tool in the fight against kidney diseases.

Renal biomarkers are measurable indicators, such as proteins or molecules found in bodily fluids, that provide valuable information about kidney function. These biomarkers help healthcare professionals in various aspects of kidney disease management. Biomarkers can detect kidney dysfunction before symptoms manifest, allowing for early intervention and improved outcomes. Renal biomarkers enable continuous monitoring of kidney function, helping doctors assess the progression of the disease and make necessary treatment adjustments.

Increased Drug Development and Clinical Trials

Renal biomarkers have become indispensable in the drug development process. They play a pivotal role in various phases of clinical trials, from patient selection and monitoring to assessing treatment efficacy and safety. Renal biomarkers help identify suitable participants for clinical trials by providing insights into the severity and stage of kidney disease. This ensures that the right patients are enrolled, improving trial accuracy and outcomes. During clinical trials, renal biomarkers are used to monitor how drugs impact kidney function. This allows researchers to assess the safety and efficacy of potential treatments. Renal biomarkers can help detect kidney-related adverse events in clinical trial participants, enabling prompt intervention and minimizing potential harm. Biomarker data can aid in the development of personalized treatment plans, allowing clinicians to tailor therapies to individual patients based on their specific kidney profiles.

In March 2024, Metyos, a medtech startup, secured USD 2.37 million in pre-seed funding, led by Cenitz and supported by KIMA Ventures, Advans Lab, Bpifrance, and various healthcare professionals and business leaders. This funding will support Metyos' development of a biowearable sensor and platform designed to enable doctors to monitor real-time biomarkers related to Chronic Kidney Disease (CKD). The technology will provide insights into kidney function, helping track the effects of diet, medication, and identify early warning signs of complications like renal failure and hyperkalemia. This innovation represents a significant advancement in drug development and clinical trials, as it offers a new way to monitor treatment efficacy and enhance patient care in CKD management. Government agencies, pharmaceutical companies, and research organizations worldwide have recognized the importance of addressing kidney diseases. Consequently, there has been a surge in initiatives, collaborations, and investments aimed at advancing renal biomarker research. These endeavors are driving innovation and accelerating the development of novel diagnostics and therapeutics. As drug development and clinical trials continue to expand, the global renal biomarkers market is poised for significant growth. Emerging technologies, such as artificial intelligence and machine learning, are enhancing our ability to identify and validate novel biomarkers quickly. Additionally, the integration of multi-omics data (genomics, proteomics, metabolomics) is providing a more comprehensive understanding of kidney diseases, leading to the discovery of new biomarkers.

Key Market Challenges

Limited Biomarker Validation

One of the primary challenges facing the renal biomarkers market is the limited validation of biomarkers. The development of reliable and accurate renal biomarkers requires extensive research and clinical trials to establish their efficacy and specificity. The validation process is time-consuming and expensive, and many potential biomarkers do not meet the necessary criteria for clinical use. As a result, the market faces a shortage of well-validated biomarkers, hindering its growth potential.

Regulatory Hurdles

Regulatory approvals are essential for the commercialization of renal biomarkers. The regulatory pathway for biomarker approval can be complex and varies from one region to another. Meeting the stringent requirements of regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) can be a lengthy and costly process. Navigating these regulatory hurdles can delay the market entry of new biomarkers and increase the overall cost of product development.

Reimbursement Challenges

Reimbursement is a critical factor in the adoption of renal biomarkers in clinical practice. Healthcare providers and payers need to determine the cost-effectiveness of using biomarkers for renal disease diagnosis and management. Convincing payers to reimburse for these tests can be challenging, especially if the cost-benefit ratio is not clearly established. Demonstrating the long-term cost savings and improved patient outcomes associated with biomarker use is essential to overcome this hurdle.

Competition and Market Saturation

The renal biomarkers market is becoming increasingly competitive, with multiple companies and research institutions vying to develop and commercialize new biomarkers. As the number of players in the market grows, it becomes harder for individual biomarkers to stand out. Market saturation can also lead to price competition, potentially affecting the profitability of biomarker developers.

Data Privacy and Ethical Concerns

With the growing use of biomarkers, concerns about data privacy and ethical issues related to patient information and biological samples have come to the forefront. Maintaining patient confidentiality and ensuring that data is used responsibly is a significant challenge, especially as biomarker research often involves extensive data collection and analysis.

Clinical Utility and Physician Adoption

For renal biomarkers to gain widespread acceptance, they must demonstrate clear clinical utility and be adopted by healthcare professionals. Physicians may be resistant to change and hesitant to incorporate new biomarkers into their diagnostic and treatment algorithms, especially if they are unfamiliar with their use or if there is insufficient evidence of their clinical benefit.

Key Market Trends

Technological Advancements

The global healthcare landscape has witnessed remarkable transformations in recent years, driven by rapid technological advancements. One area that has benefited significantly from these innovations is the diagnosis and treatment of renal diseases. The Global Renal Biomarkers Market is experiencing substantial growth as cutting-edge technologies continue to reshape the way we understand, diagnose, and manage renal conditions. Renal biomarkers are playing a pivotal role in this evolution, enabling early detection, precise diagnosis, and personalized treatment plans.

The development of advanced diagnostic tools, such as mass spectrometry and next-generation sequencing, has revolutionized the identification of renal biomarkers. These technologies allow for the rapid and accurate analysis of biological samples, enabling the detection of even subtle changes in renal function. Data analytics and artificial intelligence (AI) have become integral to the analysis of renal biomarker data. AI algorithms can process vast amounts of patient data, identifying patterns and trends that may be missed by human clinicians. This enhances the accuracy of renal disease diagnosis and the prediction of disease progression. Technological advancements have enabled the move toward personalized medicine in the field of nephrology. Renal biomarkers are used to tailor treatment plans to individual patients, taking into account their unique genetic makeup and disease characteristics. This approach improves treatment outcomes and reduces the risk of adverse effects. Miniaturization and portable diagnostic devices have made it possible to perform renal biomarker testing at the point of care. This is particularly important in remote or underserved areas where access to centralized laboratories may be limited. Point-of-care testing allows for quicker diagnosis and treatment initiation.

Segmental Insights

Product Type Insights

Based on Product Type, the Serum Cystatin C emerged as the fastest growing segment in the global Market for Renal Biomarkers Market during the forecast period. Serum Cystatin C is rapidly becoming the fastest-growing biomarker in the global renal biomarkers market, driven by its superior sensitivity and accuracy in detecting early-stage kidney dysfunction. Compared to traditional markers like creatinine, Serum Cystatin C provides more reliable results, as it is less influenced by variables such as age, gender, and muscle mass. This makes it particularly valuable for diagnosing and monitoring Chronic Kidney Disease (CKD), especially in its early stages, allowing for more timely interventions. With a growing emphasis on early detection, personalized treatment, and improved patient outcomes, the demand for Serum Cystatin C is increasing. Additionally, its expanding use in clinical trials, research, and diagnostics is further accelerating its market growth. The biomarker's adoption is also being driven by advancements in healthcare technologies, making it a key player in both developed and emerging markets.

End user Insights

Based on end user, Hospitals & Clinics emerged as the dominating segment in the global Market for Renal Biomarkers Market in 2024. Hospitals and clinics are primary healthcare settings where patients seek medical care, including kidney-related issues. These institutions see a high volume of patients with diverse medical conditions, making them key locations for renal biomarker testing. This sheer patient access ensures a consistent demand for renal biomarkers. Hospitals, in particular, are equipped with advanced diagnostic laboratories and imaging equipment. This infrastructure enables healthcare professionals to conduct a wide range of tests, including renal biomarker assays, with precision and efficiency. This makes hospitals and clinics natural hubs for renal biomarker testing. Renal biomarkers are often used in conjunction with other diagnostic tools and tests. Hospitals and clinics offer a multidisciplinary approach to healthcare, bringing together specialists from various fields such as nephrology, cardiology, and endocrinology. This approach facilitates comprehensive patient evaluation and accurate diagnosis. Many hospitals are affiliated with research institutions and universities, which fosters a culture of innovation and continuous research in the medical field. This environment promotes the development of new renal biomarkers and the improvement of existing ones. The rising global prevalence of chronic diseases, including diabetes and hypertension, has led to a surge in kidney-related conditions. Hospitals and clinics are at the forefront of managing these chronic diseases, resulting in an increased need for renal biomarker testing.

Regional Insights

Based on Region, North America emerged as the dominant region in the Global Renal Biomarkers Market in 2024. The rising prevalence of Chronic Kidney Disease (CKD) in North America is fueling the demand for effective diagnostic tools, including renal biomarkers. According to the United States Renal Data System 2023 report, over 808,000 individuals in the U.S. are living with end-stage renal disease (ESKD), with 68% undergoing dialysis and 32% having received a kidney transplant. Males are 1.6 times more likely to develop ESKD than females. The increasing incidence of kidney disease, combined with an aging population, underscores the need for early, reliable detection methods. North America, particularly the U.S. and Canada, boasts advanced healthcare systems and facilities, enabling the rapid adoption of cutting-edge technologies like renal biomarkers. Additionally, the region leads in research and development, with robust funding from both public and private sectors, driving the discovery and validation of new biomarkers. Regulatory bodies such as the U.S. FDA and Health Canada have established clear approval pathways, expediting market access for novel products. North America's prominence in clinical trials and the integration of AI, machine learning, and precision medicine further contribute to the region's leadership in renal healthcare solutions, positioning it as a dominant force in the renal biomarkers market.

Key Market Players

  • Abbott Laboratories
  • Beckman Coulter Inc. (Danaher Corporation)
  • bioMerieux SA
  • BioPorto A/S
  • Bio-Rad Laboratories Inc.
  • Enzo Biochem Inc.
  • F. Hoffmann-La Roche AG
  • PerkinElmer Inc.
  • Randox Laboratories Ltd.
  • Siemens AG
  • Thermo Fisher Scientific Inc.

Report Scope:

In this report, the Global Renal Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Renal Biomarkers Market, By Product Type:

  • Functional Biomarker
  • Serum Creatinine
  • Serum Cystatin C
  • Urine Albumin
  • Up-regulated Protein
  • Neutrophil Gelatinase-Associated Lipocalin (NGAL)
  • Kidney Injury Molecule-1
  • INTERLEUKIN-18
  • Others

Renal Biomarkers Market, By Technique:

  • Enzyme-linked Immunosorbent Assay (ELISA)
  • Particle-enhanced Turbidimetric Immunoassay (PETIA)
  • Colorimetric Assay
  • Chemiluminescent Enzyme Immunoassay (CLIA)
  • Liquid Chromatography Mass Spectrometry (LC-MS)

Renal Biomarkers Market, By End user:

  • Hospitals & Clinics
  • Diagnostic Laboratory
  • Others

Renal Biomarkers Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Renal Biomarkers Market.

Available Customizations:

Global Renal Biomarkers market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Renal Biomarkers Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product Type (Functional Biomarker, Serum Creatinine, Serum Cystatin C, Urine Albumin, Up-regulated Protein, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule-1, INTERLEUKIN-18, Others)
    • 4.2.2. By Technique (Enzyme-linked Immunosorbent Assay (ELISA), Particle-enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass Spectrometry (LC-MS))
    • 4.2.3. By End user (Hospitals & Clinics, Diagnostic Laboratory, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Product Type
    • 4.3.2. By Technique
    • 4.3.3. By End user
    • 4.3.4. By Region

5. Asia Pacific Renal Biomarkers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type
    • 5.2.2. By Technique
    • 5.2.3. By End user
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Renal Biomarkers Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Product Type
        • 5.3.1.2.2. By Technique
        • 5.3.1.2.3. By End user
    • 5.3.2. India Renal Biomarkers Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Product Type
        • 5.3.2.2.2. By Technique
        • 5.3.2.2.3. By End user
    • 5.3.3. Australia Renal Biomarkers Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Product Type
        • 5.3.3.2.2. By Technique
        • 5.3.3.2.3. By End user
    • 5.3.4. Japan Renal Biomarkers Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Product Type
        • 5.3.4.2.2. By Technique
        • 5.3.4.2.3. By End user
    • 5.3.5. South Korea Renal Biomarkers Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Product Type
        • 5.3.5.2.2. By Technique
        • 5.3.5.2.3. By End user

6. Europe Renal Biomarkers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Technique
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Renal Biomarkers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Technique
        • 6.3.1.2.3. By End user
    • 6.3.2. Germany Renal Biomarkers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Technique
        • 6.3.2.2.3. By End user
    • 6.3.3. Spain Renal Biomarkers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Technique
        • 6.3.3.2.3. By End user
    • 6.3.4. Italy Renal Biomarkers Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Product Type
        • 6.3.4.2.2. By Technique
        • 6.3.4.2.3. By End user
    • 6.3.5. United Kingdom Renal Biomarkers Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Product Type
        • 6.3.5.2.2. By Technique
        • 6.3.5.2.3. By End user

7. North America Renal Biomarkers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Technique
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Renal Biomarkers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Technique
        • 7.3.1.2.3. By End user
    • 7.3.2. Mexico Renal Biomarkers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Technique
        • 7.3.2.2.3. By End user
    • 7.3.3. Canada Renal Biomarkers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Technique
        • 7.3.3.2.3. By End user

8. South America Renal Biomarkers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Technique
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Renal Biomarkers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Technique
        • 8.3.1.2.3. By End user
    • 8.3.2. Argentina Renal Biomarkers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Technique
        • 8.3.2.2.3. By End user
    • 8.3.3. Colombia Renal Biomarkers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Technique
        • 8.3.3.2.3. By End user

9. Middle East and Africa Renal Biomarkers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Technique
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Renal Biomarkers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Technique
        • 9.3.1.2.3. By End user
    • 9.3.2. Saudi Arabia Renal Biomarkers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Technique
        • 9.3.2.2.3. By End user
    • 9.3.3. UAE Renal Biomarkers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Technique
        • 9.3.3.2.3. By End user
    • 9.3.4. Egypt Renal Biomarkers Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Product Type
        • 9.3.4.2.2. By Technique
        • 9.3.4.2.3. By End user

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Renal Biomarkers Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Abbott Laboratories
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Beckman Coulter Inc. (Danaher Corporation)
  • 14.3. bioMerieux SA
  • 14.4. BioPorto A/S
  • 14.5. Bio-Rad Laboratories Inc.
  • 14.6. Enzo Biochem Inc.
  • 14.7. F. Hoffmann-La Roche AG
  • 14.8. PerkinElmer Inc.
  • 14.9. Randox Laboratories Ltd.
  • 14.10. Siemens AG
  • 14.11. Thermo Fisher Scientific Inc.

15. Strategic Recommendations

16. About Us & Disclaimer